ATRS 1903
Alternative Names: ATRS-1903Latest Information Update: 24 Nov 2022
Price :
$50 *
At a glance
- Originator Antares Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 24 Nov 2022 Preclinical trials in Unspecified in USA (unspecified route) (Antares Pharma Pipeline, November 2022)